Join us to expand the horizons of
your pharma business!
Meet our
Dr.Reddy’s API team at
CPHI India, 2023
28th-30th November 2023
India Expo Centre, Delhi NCRBooth No - RH.I02
Our Team at CPHI India 2023
-
Deepak Sapra
CEO, Pharmaceutical Services And Active Ingredients
-
Mohammad Azharuddin Khan
Vice President, API Sales & Marketing
-
Karun Gaur
Vice President - SEMEA
-
Siddhartha Deshpande
Associate Vice president - SEMEA
-
Netraja Patil
Associate Director, Sales and Marketing - Turkey, Africa
-
Rohit Dash
Director
-
Vishal N Bhojak
Director, Sales and Marketing
-
Susmit Dey
Director, Sales and Marketing
About CPHI India 2023
CPHI India 2023, one of the leading pharmaceutical trade shows, is a highly anticipated event that brings together industry professionals and stakeholders from around the world.
Showcasing the latest innovations, technologies, and trends in the pharmaceutical sector, it serves as an essential platform for networking, knowledge sharing, and business opportunities. Join us in person at the India Expo Centre, Greater Noida, Delhi NCR, from November 28th to 30th, 2023.
At CPHI India, you'll have the opportunity to attend insightful conferences and seminars with renowned experts, foster business collaborations with potential clients, and discuss critical industry topics while witnessing prospects and innovations.
Don't miss out on this transformative event!
Schedule your meeting with our team today and be a part of CPHI India 2023!
About Dr.Reddy’s API Business
We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.
Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.
Sustainability
Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.
Our Achievement
2021
21/01/2021
Best Supply Chain Team
of the Year - Pharma- 2021
2021
11/11/2021
The winner of the Corporate
social responsibility (CSR)
Initiative of the year at Global
generics & Biosimilars Awards
2021
07/10/2021
The winner of the Best Indian
Company in the US -
Manufacturing
Sector for the year 2021
COVID-19: Prime Minister
of India Meets Pharma leaders
On October 23, 2021, Prime Minister Narendra
Modi met Indian COVID-19 vaccine manufacturers,
including Dr. Reddy's. During the meeting,
2021
21/01/2021
Best Supply Chain Team
of the Year - Pharma- 2021
2021
11/11/2021
The winner of the Corporate
social responsibility (CSR)
Initiative of the year at Global
generics & Biosimilars Awards
2021
07/10/2021
The winner of the Best Indian
Company in the US -
Manufacturing
Sector for the year 2021
COVID-19: Prime Minister
of India Meets Pharma leaders
On October 23, 2021, Prime Minister Narendra
Modi met Indian COVID-19 vaccine manufacturers,
including Dr. Reddy's. During the meeting,
Manufacturing Location
免责声明
本目錄中的任何信息（包括對任何產品或服務的任何引用）均不構成銷售要約，或被解釋為代表銷售要約。受有效專利保護的產品不提供或供應用於商業用途。但是，只要存在此類監管豁免，就可以出於監管提交的目的提供此類產品的研究數量。買方應對各自市場的專利方案進行獨立評估，並承擔所有與專利相關的責任。在印度受有效專利保護的產品不可用於商業用途，但可用於第 107A 節。